Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 26, 2006

Juvaris BioTherapeutics Gets SBIR Grant to Develop AML Vaccine Technology

  • Juvaris BioTherapeutics was awarded a one-year Phase I SBIR grant from the NCI in collaboration with David Claxton, M.D., at Penn State College of Medicine to develop a therapeutic vaccine approach for acute myelogenous leukemia (AML). Juvaris’ vaccine technology will be tested in rodent tumor models to evaluate its impact using an antigen-specific immunotherapeutic AML vaccine (JuvaVax).

    The SBIR grant application was supported by preclinical data generated by Juvaris and Dr. Claxton demonstrating significant protection in a rodent tumor model.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »